SG Americas Securities LLC Sells 102,210 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

Key Points

• SG Americas Securities cut its BioCryst stake by 44.7% in Q4, selling 102,210 shares and leaving it with 126,685 shares (about 0.06% of the company) valued at $988,000.
• Q4 results beat expectations: BioCryst reported $1.12 EPS vs. $0.07 consensus and revenue of $163.3M, a 209% year‑over‑year increase.
• Insider Alane P. Barnes sold 150,000 shares at an average $9.15 (a 27.24% reduction in their holding); institutional investors now own about 85.88% of the stock.

SG Americas Securities LLC lessened its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 44.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 126,685 shares of the biotechnology company's stock after selling 102,210 shares during the period. SG Americas Securities LLC owned approximately 0.06% of BioCryst Pharmaceuticals worth $988,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of BCRX. Deerfield Management Company L.P. increased its stake in BioCryst Pharmaceuticals by 159.4% in the third quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company's stock valued at $92,363,000 after purchasing an additional 7,477,000 shares in the last quarter. Qube Research & Technologies Ltd increased its holdings in shares of BioCryst Pharmaceuticals by 152.3% in the second quarter. Qube Research & Technologies Ltd now owns 2,373,489 shares of the biotechnology company's stock worth $21,266,000 after acquiring an additional 1,432,824 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of BioCryst Pharmaceuticals by 97.9% in the second quarter. Bank of America Corp DE now owns 2,841,155 shares of the biotechnology company's stock worth $25,457,000 after acquiring an additional 1,405,498 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in shares of BioCryst Pharmaceuticals by 1,059.7% in the second quarter. BNP Paribas Financial Markets now owns 1,456,857 shares of the biotechnology company's stock worth $13,053,000 after acquiring an additional 1,331,230 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of BioCryst Pharmaceuticals by 6.1% in the third quarter. Vanguard Group Inc. now owns 21,790,881 shares of the biotechnology company's stock worth $165,393,000 after acquiring an additional 1,246,633 shares in the last quarter. Institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Trading Up 1.1%

BioCryst Pharmaceuticals stock opened at $9.89 on Friday. The company has a market cap of $2.48 billion, a P/E ratio of 8.24 and a beta of 0.70. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.00 and a 1-year high of $11.31. The company has a fifty day simple moving average of $8.26 and a 200 day simple moving average of $7.59.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its earnings results on Thursday, February 26th. The biotechnology company reported $1.12 earnings per share for the quarter, beating analysts' consensus estimates of $0.07 by $1.05. The business had revenue of $163.28 million during the quarter, compared to the consensus estimate of $151.32 million. BioCryst Pharmaceuticals had a net margin of 30.16% and a negative return on equity of 84.33%. The firm's revenue for the quarter was up 209.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.13) earnings per share. On average, equities research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

Wall Street Analysts Forecast Growth

BCRX has been the subject of several recent analyst reports. Weiss Ratings upgraded BioCryst Pharmaceuticals from a "sell (d-)" rating to a "hold (c)" rating in a report on Wednesday, March 4th. Royal Bank Of Canada lowered their price target on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an "outperform" rating for the company in a report on Friday, January 30th. Evercore started coverage on BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They issued an "outperform" rating and a $17.00 price target for the company. Finally, HC Wainwright increased their price objective on shares of BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the stock a "buy" rating in a research report on Monday, December 15th. Ten research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $19.64.

Insiders Place Their Bets

In related news, insider Alane P. Barnes sold 150,000 shares of the firm's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $9.15, for a total value of $1,372,500.00. Following the completion of the transaction, the insider owned 400,703 shares of the company's stock, valued at approximately $3,666,432.45. This trade represents a 27.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 5.10% of the company's stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company's first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.

Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.